The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial assessed cardiovascular outcomes in high-risk hypertensive patients receiving either candesartan or amlodipine. The aim of this study was to examine the role of pre-existing diabetes or obesity on these outcomes as a sub-analysis of the trial. We examined the influence of pre-existing diabetes on cardiovascular morbidity and mortality using a multivariate Cox regression model. The cardiovascular morbidity and mortality of candesartan and amlodipine were compared between subgroups with or without pre-existing diabetes or by body mass index (BMI) category, and new-onset diabetes was compared by BMI category. Pre-existing diabetes greatly increased the cardiovascular mortality and morbidity, regardless of the allocated drugs. Furthermore, all-cause mortality was significantly higher with amlodipine than with candesartan among patients with BMI X27.5 kg m À2 (adjusted hazard ratio (HR)¼0.32; range¼0.13-0.75; P¼0.009). New-onset diabetes occurred significantly less frequently with candesartan than with amlodipine, with an adjusted HR of 0.66 (P¼0.043). Furthermore, the increase in new-onset diabetes was dependent on BMI among patients receiving amlodipine, whereas no such dependency was observed for candesartan (interaction P¼0.016). In conclusion, preexisting diabetes increased the risk of experiencing a cardiovascular event among high-risk Japanese hypertensive patients. Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity.
INTRODUCTION
Hypertension is often associated with insulin resistance, and hypertensive patients tend to develop type 2 diabetes mellitus (DM), which increases the risk of cardiovascular (CV) events in these patients. Hypertension, insulin resistance, obesity and dyslipidemia frequently occur together in a single individual, and such clustering is recognized as metabolic syndrome. With the prevalence of obesity increasing worldwide, even in Asian nations, 1 researchers have sought to develop treatment options capable of comprehensively addressing these risk factors in hypertensive patients.
As preexisting DM and obesity are thought to be related to the renin-angiotensin system (RAS), considerable interest has been focused on the difference between the treatment effects of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and calcium channel blockers (CCBs) with regard to treating hypertensive patients with DM or obesity. Several large randomized clinical trials have found the therapeutic benefits from ARBs, 2 CCBs 3, 4 and ACEIs 5 to be superior to beta blocker-based treatments or placebos with regard to reducing mortality and CV events in these patients. The Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC) conducted an individual patient-based meta-analysis and concluded that all of the major classes of blood pressure (BP)-lowering agents are capable of producing substantial reductions in short-to medium-term risk associated with the leading causes of death and CV events in patients with diabetes, although small differences in the effects of regimens on macrovascular events cannot be excluded. 6 However, none of the previous trials have analyzed the relationship between obesity and antihypertensive treatment effects on cardiovascular outcomes.
With regard to new-onset DM, the ARB, valsartan, has been shown to suppress incidence of new-onset DM more effectively than the CCB, amlodipine. 7 We recently reported the principal results of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) study, a prospective, multi-center, open-label randomized controlled trial with blinded assessment of end points, which was designed to evaluate the efficacy of candesartan and amlodipine in reducing the incidence of CV morbidity and mortality in a Japanese population with high-risk hypertension. 8 Although results ultimately showed no significant difference in incidence of CV events between the two treatments, 9 of particular note among the findings was the fact that the ARB, candesartan, prevented new-onset DM more effectively than amlodipine, thereby raising the possibility that candesartan's treatment effect may be affected by obesity condition, given present knowledge regarding the mechanism of ARB action.
To clarify the role of preexisting DM and obesity in the findings of the CASE-J trial, we evaluated the influence of diabetic status and body mass index (BMI) on trial outcomes and the interaction between these factors and allocated treatments. Preliminary data have been described previously, 9 and here we present a detailed post-hoc analysis.
METHODS

Study design
As the rationale and complete design of the CASE-J trial have been previously published, 8 relevant details are briefly described below. For the trial, written informed consents were obtained from all patients before enrollment, and the trial protocol was approved by the ethics committee of Kyoto University and undertaken in accordance with the Declaration of Helsinki Principles. The data and safety monitoring board made periodic recommendations to the steering committee regarding the ethical aspects of trial continuation by evaluating each occurrence of a possible adverse event.
The CASE-J trial enrolled eligible Japanese hypertensive patients with, at least, one high-risk factor. High-risk factors in the CASE-J trial were as follows: severe hypertension that is systolic BP (SBP) X180 mm Hg or diastolic BP (DBP) X110 mm Hg on two consecutive visits; type 2 DM (fasting blood glucose X126 mg per 100 ml, casual blood glucose X200 mg per 100 ml, hemoglobin A1c (HbA1c) X6.5%, 2-h blood glucose on 75 g oral glucose tolerance test X200 mg per 100 ml, or currently receiving treatment with a hypoglycemic agent); history of cerebral hemorrhage, cerebral infarction or transient ischemic attack occurring more than 6 months before screening; left ventricular hypertrophy on either echocardiography or electrocardiogram, angina pectoris or history of myocardial infarction occurring more than 6 months before screening; proteinuria or serum creatinine (sCr) X1.3 mg per 100 ml; and symptoms of arteriosclerotic peripheral artery obstruction.
After randomization, patients were allocated to receive either candesartan by oral administration at 4-8 mg day À1 , increasing up to 12 mg day À1 as necessary (or 2 mg day À1 , increasing up to 8 mg day À1 as necessary in patients with renal impairment) or amlodipine by oral administration at 2.5-5 mg day À1 , increasing up to 10 mg day À1 as necessary. Targets for BP control were determined according to practice guidelines developed by the Japanese Society of Hypertension (JSH), 10 as reported previously. 8 
Outcome measures
Outcome measures evaluated in this analysis were CV event, non-renal CV event, all-cause death, CV death and new-onset DM. In the original CASE-J trial, CV event was the primary end point, which is the first fatal or non-fatal CV event and represented a composite of the following: sudden unexpected death that happened within 24 h without external causes; cerebrovascular events including stroke or transient ischemic attack; cardiac events including heart failure, angina pectoris or acute myocardial infarction; renal events, including sCr X4.0 mg per 100 ml, doubling of sCr (although sCr p2.0 mg per 100 ml in any context was not regarded as an event) and endstage renal disease; and vascular events, including dissecting aortic aneurysm or arteriosclerotic occlusion of a peripheral artery. As renal pathology in diabetic patients is affected by glycemic control, we also evaluated the incidence of nonrenal CV events that excluded renal events from primary CV events. All-cause death and new-onset diabetes were the secondary and pre-specified end point in the CASE-J trial. Event evaluation for CV event and all-cause death was independently performed by the event evaluation committee members, who were blinded to the assigned treatment groups and assessed events according to the protocol criteria. Cases of new-onset DM were defined as patients who were reported to have developed DM as an adverse event or who were on anti-diabetic agents during the course of the study as reported in the case report form.
Statistical methods
Baseline characteristics were expressed as mean ± s.d. or proportions, and between-groups using the w 2 test or t-test. Analyses were divided into two parts: we first evaluated the influence of preexisting DM at baseline on each end point as a prognostic factor analysis. Here, we conducted multivariate Cox regression analysis with adjustment for allocated drugs, BMI, age, sex, hyperlipidemia, smoking history, high-risk factors in the CASE-J trial (severe hypertension, cerebrovascular history, cardiac complications, renal dysfunction and vascular disease) and antihypertensive drug use at baseline.
We then conducted a comparison with regard to allocated drugs (candesartan vs. amlodipine) across subgroups for baseline presence or absence of preexisting DM and the BMI category (o22.0, X22.0-25.0, X25.0-o27.5 and 
X27.5 kg m À2
). The cutoff points of the BMI category (22 kg m À2 as normal BMI for the Japanese; 25 kg m À2 as upper limit of normal BMI range; and 27.5 kg m À2 as the mid-point of the overweight BMI range) were pre-specified before analyzing the data. In the comparison between candesartan and amlodipine, hazard ratios (HRs), 95% confidence intervals (CIs) and P-values of the Wald test were also calculated with adjustment for age, sex, smoking history, hyperlipidemia, severe hypertension, cerebrovascular history, cardiac complications, renal dysfunction and antihypertensive drug use at baseline in the multivariate Cox regression model. Interactions of HRs between allocated drugs and the baseline variables of preexisting DM status and BMI (as continuous variable) were also evaluated in the multivariate Cox regression model with interaction terms. All statistical tests were two-sided and performed using SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Baseline characteristics and medication adherence
Of the 4703 patients that enrolled in the CASE-J trial, 2018 (42. 9%) patients had DM at baseline and 2685 (57.1%) did not. Table 1a summarizes the baseline characteristics by diabetic status at baseline and allocated drug. With regard to between-group comparisons, background characteristics were well balanced between both treatment groups except in regards to sex ratio and smoking history in patients without DM at baseline. The baseline characteristics of the BMI category were shown in Table 1b . There were some statistical differences in sex and current smoking history between two groups in the two BMI categories (o22.0 and X25.0-o27.5 kg m À2 , respectively), whereas there was no statistical difference in the BMI X27.5 kg m À2 category. Percentages of patients who took more than 80% of the allocated drug and details regarding the distribution of additional drugs during the follow-up period have already been reported in the main results of the CASE-J trial. 9 Regarding drug doses, 59.4% of patients in the candesartan group were taking 8 mg at last follow-up, whereas 23.5% were taking 12 mg and 13.8% were taking 4 mg. In the amlodipine group, 71.6% were taking 5 mg at last follow-up, whereas 14.9% were taking 10 mg and 9.5% were taking 2.5 mg. Mean doses in the candesartan and amlodipine groups were 8.3 and 5.6 mg, respectively.
Association of diabetic status at baseline with the CASE-J trial outcome Over 3.3 ± 0.8 mean years of follow-up, primary CV events occurred in 103 (3.8%) patients without DM at baseline (11.8 per 1000 patient-years) and in 165 (8.2%) with DM at baseline (25.5 per Diabetes and obesity in the CASE-J trial K Nakao et al 1000 patient-years). Multivariate Cox regression analysis revealed that DM was an independent predictor of primary CV events (adjusted HR¼2.58, 95% CI¼1.99-3.33, Po0.0001; Table 2 ), as were aging, cerebrovascular history, cardiac complications, renal dysfunction and antihypertensive drug use at baseline. In addition, DM was significantly associated with risk of each CV event and all-cause death (Table 3) .
We then examined the effects of candesartan-and amlodipinebased regimens on the incidences of each event and all-cause deaths among subgroups of diabetic status at baseline, with analysis revealing no significant differences in event incidence between the two treatment regimens, regardless of diabetic status at baseline (Table 4) . Newonset DM occurred in 38 (2.8%) patients receiving candesartan-based regimens (8.7 per 1000 patient-years) and in 59 (4.4%) receiving amlodipine-based regimens (13.6 per 1000 patient-years). Multivariate Cox regression analysis also revealed that candesartan suppressed the incidence of new-onset DM to significantly greater degree than amlodipine (adjusted HR¼0.66, 95% CI¼0.43-0.99, P¼0.043). This adjusted HR was comparable with the unadjusted one reported previously. 9 Association of BMI at baseline with the CASE-J trial outcomes The actual number and incidence rate of primary CV events, nonrenal CV events, and all-cause death in each BMI category are shown in Table 5 . No significant difference in incidence of primary and nonrenal CV events was noted between the two treatment regimens in any of the four BMI categories. With regard to all-cause death, incidence in both regimens was most frequent in the lowest BMI category (o22.0 kg m À2 ). Incidence was similar between treatment regimen groups at BMI o22.0 kg m À2 ; 22.0pBMIo25.0 kg m À2 ; and 25.0pBMIo27.5 kg m À2 . However, a statistically significant difference was noted in the incidence among patients in the BMIX27.5 kg m À2 category, with an adjusted HR of 0.32 (95% CI¼0.13-0.75, P¼0.009). Furthermore, in this category, deaths from both CV (three in the candesartan group and eight in the amlodipine group) and non-CV causes (four in the candesartan group and 12 in the amlodipine group) were more frequent in the amlodipine group than in the candesartan group, although the number of events was small. Diabetes and obesity in the CASE-J trial K Nakao et al Table 5 describes the number of patients with new-onset DM and the adjusted HRs in each category stratified according to BMI at study enrollment. In BMI subgroup analyses, candesartan significantly suppressed new-onset DM in the BMI X27.5 kg m À2 category (adjusted HR¼0.35, 95% CI¼0.13-0.94, P¼0.036) compared with amlodipine. Figure 1 clearly shows that the increase in new-onset DM was dependent on BMI in the amlodipine group, whereas no such dependency was observed in the candesartan group, highlighting the statistically significant interaction between BMI and treatment group (interaction P¼0.016).
DISCUSSION
In this analysis, we noted that DM was a strong risk factor for CV events among high-risk Japanese hypertensive patients, in addition to all-cause death, and other outcomes of the CASE-J trial. Furthermore, we showed that the ARB, candesartan, exerted a favorable effect in suppressing new-onset DM among patients with elevated BMI. However, no difference in occurrence of primary CV events was noted between candesartan and amlodipine groups regardless of diabetic status and BMI, albeit these findings had insufficient statistical power.
Previous studies that showed a decrease in the new-onset DM with antihypertensive treatment did not report the influence of BMI on the outcome. 5, 7 In our analysis, the incidence of new-onset DM was lower in patients with relatively low BMI than in those with relatively high BMI in the amlodipine group, suggesting that onset of DM is affected by the degree of patient obesity in this group. However, no such dependency was observed in patients receiving candesartan. When we conducted the additional post-hoc analysis with quintile cutoff points of the BMI category (o21.6, X21.6-23.4, X23.4-o25.1, X25.1-o27.2 and X27.2 kg m À2 ), the similar dependency was observed compared with that based on the pre-specified cutoff points of the BMI category (data not shown). These results suggested that candesartan reduced the new-onset DM by preventing the metabolically deleterious effects of increased adiposity in high-risk hypertensive patients.
The average BMI of participants in the CASE-J trial was approximately 25 kg m À2 among patients diabetic at enrollment and 24 kg m À2 among non-diabetic patients. As reported previously, 9 patients with a BMI greater than or equal to 27.5 kg m À2 , who were receiving candesartan had a significantly lower risk of all-cause death than those receiving amlodipine, whereas incidence of all-cause death was similar between the two treatment groups among patients occupying lower BMI strata. A U-shaped association between allcause death and BMI in a Japanese population has been previously reported, 11 and this same relationship was also observed between allcause death and BMI among patients receiving amlodipine in this study. In contrast, no increase in all-cause death associated with increased BMI was observed for patients receiving candesartan (Table 5) ; results we interpret to indicate that candesartan treatment reduced the incidence of all-cause death among patients whose BMI was in the highest category, who might otherwise have suffered increased mortality.
The improvement in the insulin resistance observed under antihypertensive treatment has been attributed in part to the direct effect of reduced blood pressure on endothelial function. However, candesartan 12 and enalapril, 13 both suppressed the development of DM in patients with congestive heart failure without hypertension, suggesting that the effect of RAS suppression on the development of DM is not necessarily a direct result of lowered BP. As angiotensinogen is produced by adipose tissue, 14 and angiotensin II has a role in increasing insulin resistance through its effects on adipocyte function, 15 the suppression of new-onset DM by candesartan may well depend on the state of adiposity and therefore be more profound in obese patients, as was observed in the present analysis. Hypertension and impaired glucose homeostasis associated with obesity can be considered a reflection of the pathophysiological process of metabolic syndrome. [16] [17] [18] The suppression of both hypertension and glucose intolerance induced by candesartan in this study supports the hypothesis that RAS does indeed have a role in obesity and the development of metabolic syndrome, and results from this and previous studies will aid in development of treatment strategies for pathological conditions associated with obesity, such as metabolic syndrome.
Several limitations to this analysis warrant mention. First, our study was conducted as a post-hoc analysis, and therefore there was also a risk that our findings might occur by chance. Second, the number of patients in each subgroup may not have been sufficient to allow for a thorough examination of the relationship between DM (or BMI) and trial outcomes. Third, patients were not vigorously tested for the presence of DM at the end, and diagnosis of new-onset DM relied solely on the attending clinician's decision to prescribe anti-diabetic medications or a report of DM in the adverse event form. According to the National Diabetes Survey in 2002, 69.6% of patients diagnosed as diabetic underwent either drug or insulin treatment. 19 Therefore, although the number of new-onset DM as defined in this study may have underestimated the overall incidence of DM, it is highly probable that a considerable portion of new-onset DM cases were included in the results. Last, we cannot accurately claim that the decrease in new-onset DM observed in this study directly affected the overall CV morbidity and mortality of non-diabetic patients. The recent CASE-J Ex study 20 may provide insights into these and other questions.
In conclusion, this analysis showed that DM increased CV risk among high-risk Japanese hypertensive patients. Candesartan treatment may produce significant suppression of all-cause death and reduced new-onset DM in patients with obesity. Results from this analysis will likely be of long-term benefit to obese hypertensive patients.
CONFLICT OF INTEREST
OT, NK, UK and ST have received honoraria for lectures from both Takeda Pharmaceutical and Pfizer Japan.
